Tenax Therapeutics (TENX)
(Delayed Data from NSDQ)
$4.18 USD
+0.04 (0.97%)
Updated Aug 9, 2024 03:59 PM ET
Pre-Market: $4.18 +0.13 (3.21%) 9:24 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Tenax Therapeutics, Inc. [TENX]
Reports for Purchase
Showing records 1 - 20 ( 49 total )
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Phase 3 TNX-103 PH-HFpEF Program Started, May Outlicense Drug Ex-U.S.
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Phase 3 TNX-103 PH-HFpEF Program Started, May Outlicense Drug Ex- U.S.
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Negotiates Global Levosimendan Rights, Versus Prior U.S. Canadian Rights
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Raises Cash, Phase 3 Enrolling, Receives Yet Another Levosimendan Patent
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Clears TNX-103 Phase 3s In PHHFpEF, 6MWD As 1EP, No CVOT Required
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
USPTO Issues Use Patent for Oral Levosimendan (TNX-103) in PH-HFpEF
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focused On Oral Levosimendan In PHHFpEF, Pivotal Trial starting in 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Patent Issuance For IV Levosimendan in PH-HFpEF Bodes Well For TNX-103
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3-Ready Assets to Address Different Types of Pulmonary Hypertension -Initiating Coverage
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Tenax Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Levosimendan?s Significant Market Potential Remains Underappreciated; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V